Policy Objectives

Today, European research groups and industrial companies, both large industries and SMEs, compete well with the USA and Asia in the field of ICT and (nano) biomedical devices to detect diseases, including cancer biomarkers.
European knowledge and expertise has led to many technological developments for non-invasive prediction, diagnosis, monitoring and prognosis tools. For European leadership to be maintained and to foster advancement of the state-of-art R&D, substantial cross-European combined R&D efforts such as the SniffPhone proposal will require adequate funding.

SniffPhone will enable the European Technology Platforms for Information and Communications Technology, Nanomedicine and Smart System Integrations to advance.
With the help of the strong, multi-disciplinary consortium, this project will take a leadership role in establishing the next generation of easy-to-use, highly-sensitive screening and monitoring tools.

SniffPhone planning includes business development elements, making the novel device attractive to ICT and biomedical markets.
European device manufacturers, JLM Innovation GmbH, Cellix Limited, microfluidic ChipShop GmbH and SIEMENS will benefit from participation in the current project to launch highly innovative SniffPhone products.
For these equipment manufacturers, SniffPhone will provide an early opportunity to commercialise devices with high potential, in the fast-growing area of non-invasive, real-time, and inexpensive ICT and biomedical tools. The participation of experienced players in the diagnostics field will guarantee the benchmarking of the novel SniffPhone technology and advance deployment.